A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body

NCT07071974 · Completed

Last updated 2026-05-28

This study compares how two different formulations of survodutide are absorbed in the body when given to healthy volunteers.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 16 people

Who can join Ages 18–55 · all sexes Healthy volunteers accepted.

Timeline Started 2025-07 · est. completion 2025-10

Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT07071974 ↗

Description as written by the study sponsor.

The main objective of this trial is to investigate relative bioavailability of BI 456906 reference formulation (Formulation A) vs. BI 456906 test formulation (Formulation B2).

Treatments tested

BI 456906 formulation A also known as Survodutide Combination Product

BI 456906 formulation A
BI 456906 formulation B2 also known as Survodutide Drug

BI 456906 formulation B2

Main thing measured	AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)
Sponsor	Boehringer Ingelheim
Conditions studied	Healthy
GLP-1 drugs	survodutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07071974 ↗